ТЯЖЕЛАЯ АПЛАСТИЧЕСКАЯ АНЕМИЯ С ЗАМЕДЛЕННЫМ  ОТВЕТОМ НА ИММУНОСУПРЕССИВНУЮ ТЕРАПИЮ:  ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ

E.M. Sadabaev; U.Zh. Tazhibaeva; A. Murzabek kyzy; A.K. Nartaeva

doi:10.54890/1694-8882-2025-1-58

E.M. Sadabaev U.Zh. Tazhibaeva A. Murzabek kyzy A.K. Nartaeva

DOI:

https://doi.org/10.54890/1694-8882-2025-1-58

Abstract

Aplastic anemia is a rare, life-threatening, and heterogeneous bone marrow blood disorder characterized by peripheral pancytopenia and bone marrow hypocellularity. It results in peripheral cytopenia with trilineage aplasia of the bone marrow. Anemia, bleeding, infection, and several other clinical symptoms are usually the first manifestations of aplastic anemia. In most cases, aplastic anemia is caused by autoimmune mechanisms that target progenitor stem cells, resulting in pancytopenia. Bone marrow transplantation is the definitive treatment for severe aplastic anemia; however, failing this option, combination immunosuppressive therapy with antithymocyte globulin and cyclosporine A is used as first-line therapy. Below, we present a case report highlighting the possible delay in response to an antithymocyte globulin protocol in the treatment of severe aplastic anemia. Regarding antithymocyte globulin, it can have various effects on the immune system, including depletion of T cells in the blood and peripheral tissues, and possibly a direct effect on hematopoietic stem cells.

Keywords:

aplastic anemia, immunosuppressive therapy, response to therapy

Author Biographies

E.M. Sadabaev, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Hospital Therapy with the Course of Hematology

U.Zh. Tazhibaeva, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Public Health and Health Care

A. Murzabek kyzy, Osh state university

Faculty of Medicine

A.K. Nartaeva, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Fundamental and Clinical physiology n.a. Academician S. Daniyarov

References

1. Садабаев Э.М., Тажибаева У.Ж., Арстанбекова М.А., Нартаева А.К., Иманалиева Ф.Э., Маматов С.М. Патогенез апластической анемии (обзор литературы). Вестник КГМА им. И.К. Ахунбаева. 2023;2:56-64. https://doi.org/10.54890/ 1694-6405_2023_2_56

2. Садабаев Э.М., Джакыпбаев О.А., Маматов С.М., Субанбаев Т.К. Эффективность иммуносупрессивной терапии у больных апластической анемией в пожилом возрасте. Клиническая геронтология. 2022;28(11-12):38-43. https://doi.org/10.26347/1607-2499202211-12038-043

3. Segel GB, Lichtman MA. Aplastic Anemia: Acquired and Inherited. In: Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DC. eds. Williams Hematology, 8th ed. McGraw-Hill Medical, New York, NY; 2010:569-590.

4. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519. https://doi.org/ 10.1182/blood-2006-03-010777

5. Camitta BM, Storb R, Thomas ED. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306(11):645-652. https://doi.org/10.1056/NEJM198203183061105

6. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101(4):1236-1242. https://doi.org/10.1182/blood-2002-04-1134

7. Yazer MH, Triulzi DJ. AABB Red Blood Cell Transfusion Guidelines: Something for Almost Everyone. JAMA. 2016;316(19): 1984-1985. https://doi.org/10.1001/ jama.2016.10887

8. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196. https://doi.org/ 10.1182/blood-2011-12-274019

9. Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S119-S125. https://doi.org/ 10.1016/j.bbmt.2009.09.013

10. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387-1394. https://doi.org/10.1038/ sj.leu.2404683

11. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9):1130-1135. https://doi.org/10.1001/ jama.289.9.1130

12. Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-18. https://doi.org/10.3324/ haematol.10075

13. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006;34(7):826-831. https://doi.org/10.1016/j.exphem.2006.03.017

14. Hattori M, Terasawa T, Tsushita K, et al. The status of antithymocyte globulin therapy for adult patients in Japan: retrospective analysis of a nationwide survey. Int J Hematol. 2008;87(1):48-55. https://doi.org/10.1007/s12185-007-0016-9

15. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93(7):2191–2195.

16. Passweg JR, Marsh JC. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematology Am Soc Hematol Educ Program. 2010;2010:36-42. https://doi.org/10.1182/asheducation-2010.1.36

17. Afable MG 2nd, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011;96(9):1269-1275. https://doi.org/10.3324/haematol.2011.042622

18. Kadia T., Ravandi F., Garcia-Manero G, Jabbour E, Borthakur G, Estrov Z, et al. 2010. Updated results of combination cytokine immunotherapy in the treatment of aplastic anemia and myelodysplastic syndrome (MDS). Blood. 2010;116:4422–4429.

19. Hayakawa J, Kanda J, Akahoshi Y, Harada N, Kameda K, Ugai T, et al. Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. Int J Hematol. 2017;105(5):578-586. https://doi.org/10.1007/s12185-017-2179-3

20. Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Eom KS, et al. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2013;92(6):817-824. https://doi.org/10.1007/s00277-013-1674-8